EMA investigates Allergan blockbuster hopeful Esmya on reports of liver damage
Safi Bello
Fierce Pharma ---------- As Allergan chases a U.S. approval for uterine fibroids drug Esmya, across the pond, regulators are investigating the treatment for liver damage.The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has launched a review of the product after four cases of serious liver damage turned up among patients, Bernstein’s Ronny Gal wrote in a note to clients. Three of those cases ended in liver transplantation, the EMA noted. To learn more click on the picture below to read the article.